立体定向放射外科对比全脑放疗治疗4至10个脑转移瘤患者:一项非随机对照试验
该前瞻性非随机对照单臂试验纳入4至10个脑转移瘤且ECOG体能状态评分≤2的患者,SRS组40例,回顾性WBRT队列按2:1选取70例并做倾向性评分匹配。SRS组中位总生存10.4个月,WBRT组6.5个月,差异未达统计学显著(HR 0.65,95%CI 0.40-1.05,P=.074);SRS组未观察到III级毒性。
要点
- SRS组中位总生存10.4个月,WBRT组6.5个月,差异未达统计学显著(HR 0.65,95%CI 0.40-1.05,P=.074)。
- SRS组中位颅内无进展生存7.1个月,WBRT组5.9个月,差异未达统计学显著(P=.28)。
- SRS组未观察到III级毒性。
核心结论
- 该试验未达到主要终点,SRS相较WBRT的总生存改善未达统计学显著,因此无法证明优效性。
- 作者认为在免疫治疗和靶向治疗时代需开展前瞻性随机试验。
研究设计与样本
- 前瞻性非随机对照单臂试验,SRS组纳入2017至2020年收治的4至10个脑转移瘤且ECOG体能状态评分≤2的患者,排除小细胞肺癌、生殖细胞肿瘤和淋巴瘤。
- 回顾性WBRT队列从2012至2017年连续治疗的患者中按2:1选取,并进行倾向性评分匹配以校正性别、年龄、原发肿瘤组织学、dsGPA评分和全身治疗等混杂因素。
- SRS采用基于直线加速器的单等中心技术,处方剂量15-20Gy×1次,处方于80%等剂量线;历史对照WBRT剂量方案为3Gy×10次或2.5Gy×14次。
- SRS组招募40例,WBRT组70例符合条件作为对照;末次随访日期为2021年7月1日。
主要发现
- SRS组中位总生存10.4个月(95%CI 9.3-NA),WBRT组6.5个月(95%CI 4.9-10.4),差异未达统计学显著(HR 0.65,95%CI 0.40-1.05,P=.074)。
- SRS组中位颅内无进展生存7.1个月(95%CI 3.9-14.2),WBRT组5.9个月(95%CI 4.1-8.8),差异未达统计学显著(P=.28)。
- SRS组未观察到III级毒性。
局限性
- 该试验为非随机对照单臂设计,WBRT对照为回顾性队列。
- 作者认为在免疫治疗和靶向治疗时代需开展前瞻性随机试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: There is no randomized evidence comparing whole-brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in the treatment of multiple brain metastases. This prospective nonrandomized controlled single arm trial attempts to reduce the gap until prospective randomized controlled trial results are available. MATERIAL AND METHODS: We included patients with 4-10 brain metastases and ECOG performance status ≤ 2 from all histologies except small-cell lung cancer, germ cell tumors, and lymphoma. The retrospective WBRT-cohort was selected 2:1 from consecutive patients treated within 2012-2017. Propensity-score matching was performed to adjust for confounding factors such as sex, age, primary tumor histology, dsGPA score, and systemic therapy. SRS was performed using a LINAC-based single-isocenter technique employing prescription doses from 15-20Gyx1 at the 80% isodose line. The historical control consisted of equivalent WBRT dose regimens of either 3Gyx10 or 2.5Gyx14. RESULTS: Patients were recruited from 2017-2020, end of follow-up was July 1st, 2021. 40 patients were recruited to the SRS-cohort and 70 patients were eligible as controls in the WBRT-cohort. Median OS, and iPFS were 10.4 months (95%-CI 9.3-NA) and 7.1 months (95%-CI 3.9-14.2) for the SRS-cohort, and 6.5 months (95%-CI 4.9-10.4), and 5.9 months (95%-CI 4.1-8.8) for the WBRT-cohort, respectively. Differences were non-significant for OS (HR: 0.65; 95%-CI 0.40-1.05; P =.074) and iPFS (P =.28). No grade III toxicities were observed in the SRS-cohort. CONCLUSION: This trial did not meet its primary endpoint as the OS-improvement of SRS compared to WBRT was non-significant and thus superiority could not be proven. Prospective randomized trials in the era of immunotherapy and targeted therapies are warranted.
引用
- Bodensohn R, Kaempfel AL, Boulesteix AL, et al. Stereotactic radiosurgery versus whole-brain radiotherapy in patients with 4-10 brain metastases: A nonrandomized controlled trial. Radiother Oncol. 2023. PMID: 37330054. doi:10.1016/j.radonc.2023.109744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。